diazoxide has been researched along with hydroflumethiazide in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (38.46) | 18.7374 |
| 1990's | 1 (7.69) | 18.2507 |
| 2000's | 1 (7.69) | 29.6817 |
| 2010's | 6 (46.15) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Gozalbes, R; Pineda-Lucena, A | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Brodsky, JL; Chiang, A; Chung, WJ; Denny, RA; Goeckeler-Fried, JL; Havasi, V; Hong, JS; Keeton, AB; Mazur, M; Piazza, GA; Plyler, ZE; Rasmussen, L; Rowe, SM; Sorscher, EJ; Weissman, AM; White, EL | 1 |
| Blayac, JP; Loubatières-Mariani, MM; Manteghetti, M; Petit, P | 1 |
| Cross, RB; Thornton, WM | 1 |
| Gulbenkian, A; Tabachnick, II; Yannell, A | 1 |
| Blayac, JP; Buys, D; Loubatieres-Mariani, MM; Puech, R; Ribes, G | 1 |
| Blayac, JP; Loubatieres-Mariani, MM; Manteghetti, M; Puech, R; Ribes, G | 1 |
| GILLENWATER, JY | 1 |
1 review(s) available for diazoxide and hydroflumethiazide
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
12 other study(ies) available for diazoxide and hydroflumethiazide
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
QSAR-based solubility model for drug-like compounds.
Topics: Databases, Factual; Models, Molecular; Pharmaceutical Preparations; Quantitative Structure-Activity Relationship; Solubility; Water | 2010 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
Topics: Alleles; Benzoates; Cells, Cultured; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Endoplasmic Reticulum; Furans; Gene Deletion; HEK293 Cells; HeLa Cells; High-Throughput Screening Assays; Humans; Hydroxamic Acids; Microscopy, Fluorescence; Protein Folding; Protein Structure, Tertiary; Pyrazoles; RNA, Messenger; Small Molecule Libraries; Ubiquitination; Vorinostat | 2016 |
Comparative effects of LN 5330 and diazoxide on insulin release and 86Rb+ permeability in perifused rat islets of Langerhans.
Topics: Animals; Calcium; Cell Membrane Permeability; Diazoxide; Glucose; Hydroflumethiazide; Insulin; Insulin Secretion; Islets of Langerhans; Kinetics; Male; Perfusion; Rats; Rats, Inbred Strains; Rubidium; Rubidium Radioisotopes | 1991 |
The effect of benzothiadiazine diuretics on the renal concentrating mechanism of the sheep.
Topics: Absorption; Animals; Bendroflumethiazide; Chlorides; Chlorothiazide; Diazoxide; Hydrochlorothiazide; Hydroflumethiazide; Kidney Tubules; Natriuresis; Potassium; Sheep; Vasopressins; Water-Electrolyte Balance | 1966 |
The hyperglycemic activity of benzothiadiazine and other diuretics.
Topics: Animals; Bendroflumethiazide; Benzothiadiazines; Chlorothiazide; Chlorthalidone; Diazoxide; Diuretics; Ethacrynic Acid; Hydroflumethiazide; Hyperglycemia; Methyclothiazide; Polythiazide; Rats; Sulfonamides; Trichlormethiazide | 1965 |
Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion.
Topics: Animals; Diazoxide; Female; Glucose; Hydroflumethiazide; In Vitro Techniques; Insulin; Insulin Secretion; Islets of Langerhans; Kinetics; Perfusion; Rats; Rats, Inbred Strains; Somatostatin; Time Factors | 1981 |
Effect of LN 5330 on insulin release and calcium uptake by isolated rat islets of Langerhans. Comparison with diazoxide.
Topics: Animals; Calcium; Calcium Radioisotopes; Diazoxide; Hydroflumethiazide; In Vitro Techniques; Insulin; Insulin Secretion; Islets of Langerhans; Male; Rats; Rats, Inbred Strains | 1984 |
THE ANTIDIURETIC PROPERTIES OF CHLOROTHIAZIDE IN DIABETES INSIPIDUS DOGS. I. EFFECT ON SOLUTE, WATER, AND ELECTROLYTE EXCRETION. REP 582.
Topics: Animals; Bendroflumethiazide; Blood Volume; Body Fluids; Chlorothiazide; Chlorthalidone; Diabetes Insipidus; Diazoxide; Diuresis; Diuretics; Dogs; Electrolytes; Hydroflumethiazide; Kidney Function Tests; Pharmacology; Research; Urine; Water | 1963 |